Related Experiment Videos
Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia
T G Sutedja1, J F Apperley, J M Hughes
1Department of Medicine, Royal Postgraduate Medical School, London.
Thorax
|March 1, 1988
Summary
Bone marrow transplants for chronic myeloid leukaemia can temporarily reduce lung function, particularly carbon monoxide transfer factor (TLCO). However, most patients show significant recovery within 24 months, with minor long-term impairment.
Area of Science:
- Pulmonology
- Hematology
- Oncology
Background:
- Bone marrow transplantation (BMT) is a curative treatment for chronic myeloid leukaemia (CML).
- Pulmonary complications can affect BMT outcomes.
- Assessing lung function post-BMT is crucial for patient management.
Purpose of the Study:
- To evaluate changes in pulmonary function after BMT for CML.
- To identify factors associated with pulmonary function decline and recovery.
Main Methods:
- Pulmonary function tests (TLCO, KCO, FEV1, VC) were performed before and at intervals up to 24 months post-BMT in 44 CML patients.
- Patients received either unmanipulated or T-cell depleted donor marrow, with varying total body irradiation (TBI) doses.
- Regression analysis identified factors influencing pulmonary function changes.
Main Results:
- Pulmonary function, especially TLCO, declined at 6 and 12 months post-BMT but showed significant recovery between 6 and 24 months.
- T-cell depleted marrow and higher TBI doses were associated with KCO decline and increased FEV1/VC ratio.
- Acute and chronic graft-versus-host disease (GVHD) correlated with reduced FEV1 and VC, respectively.
Conclusions:
- Most patients experience transient pulmonary function impairment after BMT for CML.
- Factors like T-cell depletion, TBI dose, and GVHD influence pulmonary outcomes.
- Long-term pulmonary impairment is generally minor for short-term survivors.